NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2400 participants.
Also called NCT02817360
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,400 participants
- Sponsor
- Martin Huelsmann
- Registry
-
NCT02817360
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria, Netherlands, New Zealand, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT02817360. Randomized; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2025-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
- Condition
- Heart Diseases
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- RAS-antagonist and beta-blocker up-to maximal dosages
- Intervention (Other)
- RAS-antagonist and beta-blocker none or at stable dose
- Lead sponsor
- Martin Huelsmann
Record details
- Record id
cardio:ct-nct02817360- Content hash
423f6df216a3a37bee65091406195a338b04f9d776847a86d55402e6deabb9e9